| Year |
Citation |
Score |
| 2021 |
Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine SM, Stone RM, et al. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Advances. PMID 34492682 DOI: 10.1182/bloodadvances.2021004813 |
0.31 |
|
| 2020 |
Elmeliegy M, Den Haese J, Talati C, Wetzler M, Jusko WJ. Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. PMID 32748108 DOI: 10.1007/S00280-020-04114-Z |
0.423 |
|
| 2018 |
Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Devine S, Smith SE, Stone RM, Larson RA. A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701 Blood. 132: 309-309. DOI: 10.1182/Blood-2018-99-120029 |
0.385 |
|
| 2017 |
Vachhani P, Shin S, Baron J, Thompson JE, Wetzler M, Griffiths EA, Ontiveros EP, Spangenthal EJ, Wang ES. Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia. Leukemia Research Reports. 7: 36-39. PMID 28462084 DOI: 10.1016/J.Lrr.2017.04.001 |
0.365 |
|
| 2017 |
Vachhani P, Freyer C, Baron J, Miller A, Wetzler M, Thompson JE, Griffiths EA, Wang ES. Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia Blood. 130: 5052-5052. DOI: 10.1182/Blood.V130.Suppl_1.5052.5052 |
0.368 |
|
| 2016 |
Pailler ME, Johnson TM, Kuszczak S, Attwood KM, Zevon MA, Griffiths E, Thompson J, Wang ES, Wetzler M. Adjustment to Acute Leukemia: The Impact of Social Support and Marital Satisfaction on Distress and Quality of Life Among Newly Diagnosed Patients and Their Caregivers. Journal of Clinical Psychology in Medical Settings. PMID 27424023 DOI: 10.1007/S10880-016-9459-6 |
0.309 |
|
| 2016 |
Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. Evolution of acute myelogenous leukemia stem cell properties following treatment and progression. Blood. PMID 27421961 DOI: 10.1182/Blood-2016-02-695312 |
0.415 |
|
| 2016 |
Griffiths EA, Brady WE, Tan W, Vigil CE, Thompson JE, Ford LA, Dickey NM, L Bashaw H, Sperrazza J, Wetzler M, Wang ES. A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia. Leukemia Research. 43: 44-48. PMID 26943703 DOI: 10.1016/J.Leukres.2016.02.003 |
0.383 |
|
| 2016 |
DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leukemia & Lymphoma. 1-9. PMID 26892479 DOI: 10.3109/10428194.2016.1144881 |
0.401 |
|
| 2016 |
Almyroudis NG, Osawa R, Samonis G, Wetzler M, Wang ES, McCarthy PL, Segal BH. Discontinuation of Systematic Surveillance and Contact Precautions for Vancomycin-Resistant Enterococcus (VRE) and Its Impact on the Incidence of VRE faecium Bacteremia in Patients with Hematologic Malignancies. Infection Control and Hospital Epidemiology. 1-6. PMID 26750087 DOI: 10.1017/Ice.2015.310 |
0.318 |
|
| 2016 |
Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Halvorson A, Devine SM, Smith S, Stone RM, Larson RA. A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance) Blood. 128: 2782-2782. DOI: 10.1182/Blood.V128.22.2782.2782 |
0.425 |
|
| 2015 |
Varallo-Rodriguez C, Freyer CW, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias. Expert Opinion On Orphan Drugs. 3: 599-608. PMID 31388478 DOI: 10.1517/21678707.2015.1036027 |
0.385 |
|
| 2015 |
Ustwani OA, Gupta N, Bakhribah H, Griffiths E, Wang E, Wetzler M. Clinical updates in adult acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology. PMID 26777876 DOI: 10.1016/J.Critrevonc.2015.12.007 |
0.342 |
|
| 2015 |
Torka P, Al Ustwani O, Wetzler M, Wang ES, Griffiths EA. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia. Blood Reviews. PMID 26709030 DOI: 10.1016/J.Blre.2015.11.004 |
0.335 |
|
| 2015 |
Wetzler M, Kantarjian HM, Nicolini FE, Lipton JH, Akard L, Baccarani M, Khoury HJ, Li E, Munteanu M, Cortes J. Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses. Blood Cancer Journal. 5: e376. PMID 26657200 DOI: 10.1038/Bcj.2015.104 |
0.443 |
|
| 2015 |
Talati C, Griffiths EA, Wetzler M, Wang ES. Polo-like kinase inhibitors in hematologic malignancies. Critical Reviews in Oncology/Hematology. PMID 26597019 DOI: 10.1016/J.Critrevonc.2015.10.013 |
0.417 |
|
| 2015 |
Akard L, Kantarjian HM, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Jean Khoury H, Kurtin S, Li E, Munteanu M, Cortes J. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leukemia & Lymphoma. 1-12. PMID 26436949 DOI: 10.3109/10428194.2015.1071486 |
0.391 |
|
| 2015 |
Muppidi MR, Portwood S, Griffiths EA, Thompson JE, Ford LA, Freyer CW, Wetzler M, Wang ES. Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. 15: S73-9. PMID 26297284 DOI: 10.1016/J.Clml.2015.02.033 |
0.417 |
|
| 2015 |
Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British Journal of Haematology. PMID 26205361 DOI: 10.1111/Bjh.13607 |
0.408 |
|
| 2015 |
Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, ... Wetzler M, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 523: 183-8. PMID 26131937 DOI: 10.1038/Nature14610 |
0.314 |
|
| 2015 |
Rogala B, Freyer CW, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opinion On Biological Therapy. 15: 895-908. PMID 25985814 DOI: 10.1517/14712598.2015.1041912 |
0.364 |
|
| 2015 |
Gupta N, Miller A, Gandhi S, Ford LA, Vigil CE, Griffiths EA, Thompson JE, Wetzler M, Wang ES. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old. American Journal of Hematology. 90: 639-46. PMID 25808347 DOI: 10.1002/Ajh.24016 |
0.422 |
|
| 2015 |
Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, et al. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1252-7. PMID 25732165 DOI: 10.1200/Jco.2014.57.0952 |
0.372 |
|
| 2015 |
Wang ES, Wetzler M. An oncologist's perspective on metformin use and acute lymphoblastic leukemia outcomes. Journal of Pharmacy Practice. 28: 46-7. PMID 25715082 DOI: 10.1177/0897190014557627 |
0.361 |
|
| 2015 |
Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. American Journal of Hematology. 90: E77-9. PMID 25651001 DOI: 10.1002/Ajh.23965 |
0.367 |
|
| 2015 |
Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Reviews. 29: 243-9. PMID 25614322 DOI: 10.1016/J.Blre.2015.01.001 |
0.41 |
|
| 2015 |
Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 121: 1637-44. PMID 25586015 DOI: 10.1002/Cncr.29240 |
0.419 |
|
| 2015 |
Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. How we will treat chronic myeloid leukemia in 2016. Blood Reviews. 29: 137-42. PMID 25555325 DOI: 10.1016/J.Blre.2014.12.003 |
0.346 |
|
| 2015 |
Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 125: 1367-76. PMID 25550361 DOI: 10.1182/Blood-2014-11-610543 |
0.428 |
|
| 2015 |
Griffiths EA, Golding MC, Srivastava P, Povinelli BJ, James SR, Ford LA, Wetzler M, Wang ES, Nemeth MJ. Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts. Haematologica. 100: e49-52. PMID 25381132 DOI: 10.3324/Haematol.2014.113118 |
0.391 |
|
| 2015 |
Freyer CW, Gupta N, Wetzler M, Wang ES. Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? American Journal of Hematology. 90: 62-72. PMID 25284482 DOI: 10.1002/Ajh.23862 |
0.398 |
|
| 2015 |
Khoury HJ, Cortes J, Baccarani M, Wetzler M, Masszi T, Digumarti R, Craig A, Benichou AC, Akard L. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leukemia & Lymphoma. 56: 120-7. PMID 24650054 DOI: 10.3109/10428194.2014.889826 |
0.408 |
|
| 2015 |
Chana A, Ford LA, Griffiths EA, Thompson JE, Wetzler M, Wang ES. Performance status and comorbidities on outcome of hypomethylating therapy in older adults (≥60 years old) with acute myeloid leukemia. Journal of Clinical Oncology. 33: 7058-7058. DOI: 10.1200/Jco.2015.33.15_Suppl.7058 |
0.391 |
|
| 2015 |
Frangou C, Den Haese J, Warunek J, Portwood S, Nowak NJ, Gudkov AV, Gurova K, Wetzler M, Wang ES. Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells Blood. 126: 1391-1391. DOI: 10.1182/Blood.V126.23.1391.1391 |
0.398 |
|
| 2015 |
Paluch B, Srivastava P, Yellayi D, Wetzler M, Griffiths E. Decitabine enhances the expression of TAP1 facilitating antigen-specific immune responses in acute myeloid leukemia Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.04.040 |
0.302 |
|
| 2015 |
Muppidi MR, Griffiths EA, Thompson JE, Ford LA, Freyer CW, Wetzler M, Wang ES. Decitabine and sorafenib therapy in FLT3-ITD mutant acute myeloid leukemia- A case series Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.04.034 |
0.49 |
|
| 2014 |
Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrõzek K, Bloomfield CD, Larson RA. Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) Cancer. 120. PMID 26437204 DOI: 10.1002/Cncr.28708 |
0.335 |
|
| 2014 |
Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, et al. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 111: 18679-84. PMID 25512507 DOI: 10.1073/Pnas.1422050112 |
0.393 |
|
| 2014 |
Deeb KK, Smonskey MT, DeFedericis H, Deeb G, Sait SN, Wetzler M, Wang ES, Starostik P. Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia. Leukemia Research Reports. 3: 86-9. PMID 25379410 DOI: 10.1016/J.Lrr.2013.09.003 |
0.328 |
|
| 2014 |
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, ... ... Wetzler M, et al. Chronic myelogenous leukemia, version 1.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1590-610. PMID 25361806 DOI: 10.6004/Jnccn.2014.0159 |
0.383 |
|
| 2014 |
Al Ustwani O, Griffiths EA, Wang ES, Wetzler M. Omacetaxine mepesuccinate in chronic myeloid leukemia. Expert Opinion On Pharmacotherapy. 15: 2397-405. PMID 25301179 DOI: 10.1517/14656566.2014.964642 |
0.373 |
|
| 2014 |
Smith MB, Griffiths EA, Thompson JE, Wang ES, Wetzler M, Freyer CW. High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure. Leukemia Research Reports. 3: 62-6. PMID 25180154 DOI: 10.1016/J.Clml.2015.04.055 |
0.389 |
|
| 2014 |
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, ... ... Wetzler M, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 26: 428-42. PMID 25132497 DOI: 10.1016/J.Ccr.2014.07.006 |
0.307 |
|
| 2014 |
Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 124: 1183-91. PMID 24963042 DOI: 10.1182/Blood-2014-04-572545 |
0.394 |
|
| 2014 |
Chen GL, Liu H, Zhang Y, Thomas J, Ross M, Wang ES, Block AW, Sait S, Deeb G, Wallace P, Wetzler M, Hahn T, McCarthy PL. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1369-74. PMID 24867777 DOI: 10.1016/J.Bbmt.2014.05.013 |
0.411 |
|
| 2014 |
Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, ... ... Wetzler M, et al. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia. 28: 1754-8. PMID 24651097 DOI: 10.1038/Leu.2014.114 |
0.311 |
|
| 2014 |
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British Journal of Haematology. 165: 497-503. PMID 24528179 DOI: 10.1111/Bjh.12775 |
0.425 |
|
| 2014 |
Akard LP, Cortes JE, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study. Archives of Pathology & Laboratory Medicine. 138: 1186-92. PMID 24308645 DOI: 10.5858/Arpa.2013-0584-Oa |
0.402 |
|
| 2014 |
Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, Wilding GE, Ford LA, Sait SN, Block AW, Adjei AA, Barcos M, Griffiths EA, Thompson JE, Wang ES, ... ... Wetzler M, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer. 120: 521-9. PMID 24166051 DOI: 10.1002/Cncr.28368 |
0.352 |
|
| 2014 |
Wetzler M, Mrózek K, Kohlschmidt J, Dombret H, Döhner H, Pilorge S, Krug U, Carroll AJ, Larson RA, Marcucci G, Hiddemann W, Büchner T, Bloomfield CD. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 99: 308-13. PMID 24097631 DOI: 10.3324/Haematol.2013.092072 |
0.437 |
|
| 2014 |
Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 99: 111-5. PMID 24077846 DOI: 10.3324/Haematol.2013.085811 |
0.376 |
|
| 2014 |
Wang ES, Fetterly GJ, Pitzonka L, Brady WE, Tan W, Greene J, Munster D, Vigil C, Mendler JH, Becker MW, Carr-O'Dwyer KM, Wetzler M, Liesveld J. Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia. Journal of Clinical Oncology. 32: 7082-7082. DOI: 10.1200/Jco.2014.32.15_Suppl.7082 |
0.383 |
|
| 2014 |
Wetzler M, Kantarjian HM, Nicolini FE, Lipton JH, Akard LP, Baccarani M, Khoury HJ, Li E, Munteanu MC, Cortes JE. Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP) phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate. Journal of Clinical Oncology. 32: 7066-7066. DOI: 10.1200/Jco.2014.32.15_Suppl.7066 |
0.406 |
|
| 2014 |
Marcucci G, Geyer S, Zhao W, Caroll AJ, Bucci D, Uy GL, Blum W, Pardee T, Wetzler M, Stock W, Kolitz JE, Eisfeld A, Bloomfield CD, Stone RM, Larson RA. Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) Blood. 124: 8-8. DOI: 10.1182/Blood.V124.21.8.8 |
0.367 |
|
| 2014 |
Alrazzak M, Hill B, Griffiths EA, Wang ES, Wetzler M, Walace PK. Minimal Residual Disease Sensitivity in Patients with Pre-B Cell Acute Lymphoblastic Leukemia Using Gemstone Analysis Method Blood. 124: 5348-5348. DOI: 10.1182/Blood.V124.21.5348.5348 |
0.372 |
|
| 2014 |
Muppidi MR, Griffiths EA, Thompson JE, Ford LA, Freyer CW, Wetzler M, Wang ES. Decitabine and Sorafenib Therapy in Patients with FLT3-ITD Mutant Acute Myeloid Leukemia Is Associated with High Response Rates—a Single Institute Experience Blood. 124: 5284-5284. DOI: 10.1182/Blood.V124.21.5284.5284 |
0.48 |
|
| 2014 |
Sanford D, LoCoco F, Sanz MA, Bona ED, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian HM, Cortes JE. Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses Blood. 124: 3751-3751. DOI: 10.1182/Blood.V124.21.3751.3751 |
0.47 |
|
| 2014 |
Griffiths EA, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Emadi A. Presence of Isocitrate Dehydrogenase (IDH) Mutations May Predict Clinical Response to Hypomethylating Agents in Patients with Acute Myeloid Leukemia (AML) Blood. 124: 3724-3724. DOI: 10.1182/Blood.V124.21.3724.3724 |
0.37 |
|
| 2014 |
Griffiths EA, Brady W, Tan W, Vigil CE, Thompson JE, Ford LA, Dickey NM, Sperrazza J, Wang ES, Wetzler M. A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia Blood. 124: 2318-2318. DOI: 10.1182/Blood.V124.21.2318.2318 |
0.404 |
|
| 2014 |
Eisfeld A, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu Y, Liyanarachchi S, Patel R, Baer MR, ... ... Wetzler M, et al. miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53 Clinical Lymphoma Myeloma and Leukemia. 14: S157. DOI: 10.1016/J.Clml.2014.06.101 |
0.306 |
|
| 2014 |
Paluch B, Srivastava P, Abrams S, Wetzler M, Griffiths E. Exposure to Decitabine (Dac), Both In Vitro and in Peripheral Blood Blasts From Acute Myeloid Leukemia (AML) Patients, Enhances the Expression of CD58 and Antigen Presentation Machinery on Leukemic Cells Clinical Lymphoma, Myeloma & Leukemia. 14. DOI: 10.1016/J.Clml.2014.06.048 |
0.368 |
|
| 2013 |
Al Ustwani O, Greene JD, Wetzler M. The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine. Leukemia Research Reports. 2: 34-5. PMID 24371774 DOI: 10.1016/J.Lrr.2013.03.002 |
0.403 |
|
| 2013 |
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, ... ... Wetzler M, et al. Chronic Myelogenous Leukemia, Version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1327-40. PMID 24225967 DOI: 10.6004/Jnccn.2013.0157 |
0.381 |
|
| 2013 |
Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart CP, Wang ES. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6506-19. PMID 24088735 DOI: 10.1158/1078-0432.Ccr-13-0674 |
0.383 |
|
| 2013 |
Vigil CE, Tan W, Deeb G, Sait SN, Block AW, Starostik P, Griffiths EA, Thompson JE, Greene JD, Ford LA, Wang ES, Wetzler M. Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. Leukemia Research. 37: 1468-71. PMID 24011826 DOI: 10.1016/J.Leukres.2013.07.036 |
0.442 |
|
| 2013 |
Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clinical Lymphoma, Myeloma & Leukemia. 13: 584-91. PMID 23787123 DOI: 10.1016/J.Clml.2013.03.020 |
0.443 |
|
| 2013 |
Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia. 13: 430-4. PMID 23763920 DOI: 10.1016/J.Clml.2013.03.015 |
0.389 |
|
| 2013 |
Al Ustwani O, Ford LA, Sait SJ, Block AM, Barcos M, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Ambrus J, Wetzler M. Myelodysplastic syndromes and autoimmune diseases--case series and review of literature. Leukemia Research. 37: 894-9. PMID 23692654 DOI: 10.1016/J.Leukres.2013.04.007 |
0.302 |
|
| 2013 |
Brady MT, Miller A, Sait SN, Ford LA, Minderman H, Wang ES, Lee KP, Baumann H, Wetzler M. Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function. Leukemia Research. 37: 822-8. PMID 23628554 DOI: 10.1016/J.Leukres.2013.04.002 |
0.317 |
|
| 2013 |
Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. American Journal of Hematology. 88: 350-4. PMID 23468307 DOI: 10.1002/Ajh.23408 |
0.44 |
|
| 2013 |
Al Ustwani O, Wetzler M. Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time? Leukemia & Lymphoma. 54: 2100-2. PMID 23410101 DOI: 10.3109/10428194.2013.776169 |
0.425 |
|
| 2013 |
Francis J, Dharmadhikari AV, Sait SN, Deeb G, Wallace PK, Thompson JE, Wang ES, Wetzler M. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leukemia & Lymphoma. 54: 1517-20. PMID 23193950 DOI: 10.3109/10428194.2012.754096 |
0.324 |
|
| 2013 |
Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RA. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 119: 90-8. PMID 22744771 DOI: 10.1002/Cncr.27617 |
0.368 |
|
| 2013 |
Ustwani OA, Ford LA, Sait SNJ, Block AMW, Barcos MP, Griffiths EA, Thompson JE, Wang ES, Ambrus JL, Wetzler M. Myelodysplastic syndrome (MDS) and autoimmune diseases (AD): Hypomethylating agents to treat both. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E18018 |
0.309 |
|
| 2013 |
Wetzler M, Kantarjian HM, Nicolini FE, Lipton JH, Akard LP, Baccarani M, Khoury HJ, Craig A, Cortes JE. Predictive factors associated with achievement of major cytogenetic response (MCyR) to omacetaxine mepesuccinate among patients with chronic phase chronic myeloid leukemia (CML-CP). Journal of Clinical Oncology. 31: 7088-7088. DOI: 10.1200/Jco.2013.31.15_Suppl.7088 |
0.412 |
|
| 2013 |
Akard LP, Kantarjian HM, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Khoury HJ, Craig A, Cortes JE. Omacetaxine mepesuccinate in chronic phase chronic myeloid leukemia (CML-CP): A post hoc analysis of myelosuppression. Journal of Clinical Oncology. 31: 7073-7073. DOI: 10.1200/Jco.2013.31.15_Suppl.7073 |
0.411 |
|
| 2013 |
Rea D, Kantarjian HM, Wetzler M, Nicolini FE, Lipton JH, Akard LP, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Legros L, Warzocha K, Parikh PM, Craig A, et al. Post hoc analysis of sustained efficacy/tolerability of ≥12 cycles of omacetaxine mepesuccinate in chronic myeloid leukemia (CML). Journal of Clinical Oncology. 31: 7066-7066. DOI: 10.1200/Jco.2013.31.15_Suppl.7066 |
0.424 |
|
| 2013 |
Frangou CG, Den Haese J, Nowak N, Johnson CS, Trump D, Wetzler M. 25(OH) Vitamin D3 Affects Acute Myeloid Leukemia Cell Proliferation Blood. 122: 5026-5026. DOI: 10.1182/Blood.V122.21.5026.5026 |
0.308 |
|
| 2013 |
Golding M, Paluch BE, Srivastava P, Liu S, Hu Q, Wetzler M, Nemeth M, Griffiths EA. Patients Treated With Decitabine Demonstrate Changes In β-Catenin Localization From The Nucleus To The Cytoplasm In Circulating Blasts Blood. 122: 3956-3956. DOI: 10.1182/Blood.V122.21.3956.3956 |
0.304 |
|
| 2013 |
Geyer S, Zhao J, Caroll AJ, Bucci D, Vij R, Blum W, Pardee T, Wetzler M, Stock W, Bloomfield CD, Larson RA, Stone RM. Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study Blood. 122: 357-357. DOI: 10.1182/Blood.V122.21.357.357 |
0.404 |
|
| 2013 |
Garcia-Manero G, Luger SM, Goldberg S, Altman JK, Arellano M, Wetzler M, Seiter K, Chiao J, Kantarjian HM. A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents Blood. 122: 2752-2752. DOI: 10.1182/Blood.V122.21.2752.2752 |
0.417 |
|
| 2013 |
Cortes JE, Wetzler M, Lipton JH, Khoury HJ, Kropf P, Michallet M, Baccarani M, Rea D, Chuah C, Digumarti R, Parikh PM, Li E, Munteanu MC, Brown PD, Nicolini FE. Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) Blood. 122: 2743-2743. DOI: 10.1182/Blood.V122.21.2743.2743 |
0.383 |
|
| 2013 |
Wang ES, Fetterly G, Brady W, Tan W, Greene J, Gaudy A, Vigil CE, Mendler JH, Becker MW, O'Dwyer K, Liesveld JL, Wetzler M. Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients Blood. 122: 2701-2701. DOI: 10.1182/Blood.V122.21.2701.2701 |
0.447 |
|
| 2013 |
Batty N, Wiles S, Kabalan M, Sharma R, Shatzel J, Pang J, Yi D, Alatovic I, Saif S, Narasimha D, LaPenna J, Troitino A, Attwood K, Yin Y, Wetzler M. Decitabine Is More Cost Effective Than Standard Conventional Induction Therapy In Elderly Acute Myeloid Leukemia Patients Blood. 122: 2699-2699. DOI: 10.1182/Blood.V122.21.2699.2699 |
0.364 |
|
| 2013 |
Gupta N, Gandhi S, Miller A, Ford LA, Griffiths EA, Thompson JE, Wetzler M, Wang ES. Comparison Of Epigenetic Versus Intensive Chemotherapy For Newly Diagnosed Acute Myeloid Leukemia Patients ≥60 Years Old: The Roswell Park Experience Blood. 122: 1445-1445. DOI: 10.1182/Blood.V122.21.1445.1445 |
0.366 |
|
| 2013 |
Wintrob ZAP, Chuang H, Miller DS, Rabey JL, Bui TQ, Amsler ME, Ford L, Wetzler M, Ceacareanu AC. Abstract LB-17: Missing the benefit of metformin in AML: A problem of contrast. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-17 |
0.366 |
|
| 2013 |
Vigil CE, Tan W, Wilding G, Garcia-Manero G, Wang ES, Wetzler M, List AF. Comparison of Outcome in Erythroleukemia Patients Treated with Standard Chemotherapy Regimens or Hypomethylating Agents Clinical Lymphoma, Myeloma & Leukemia. 13. DOI: 10.1016/J.Clml.2013.07.090 |
0.364 |
|
| 2013 |
Vigil CE, Griffiths EA, Thompson JE, Brady WE, Dickey NM, Ford LA, Wang ES, Wetzler M. A Phase I Trial of Lenalidomide in Combination with Intermediate Dose Cytarabine (IDC) in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients Clinical Lymphoma, Myeloma & Leukemia. 13. DOI: 10.1016/J.Clml.2013.07.089 |
0.433 |
|
| 2012 |
Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. The Lancet. Oncology. 13: 1096-104. PMID 23075701 DOI: 10.1016/S1470-2045(12)70436-9 |
0.369 |
|
| 2012 |
Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling. Leukemia Research. 36: 1410-6. PMID 22884950 DOI: 10.1016/J.Leukres.2012.07.015 |
0.308 |
|
| 2012 |
Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, ... ... Wetzler M, et al. Acute lymphoblastic leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 858-914. PMID 22773801 DOI: 10.6004/Jnccn.2012.0089 |
0.334 |
|
| 2012 |
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3109-18. PMID 22753902 DOI: 10.1200/Jco.2011.40.6652 |
0.393 |
|
| 2012 |
Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2492-9. PMID 22585697 DOI: 10.1200/Jco.2011.37.9743 |
0.404 |
|
| 2012 |
Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrózek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, ... ... Wetzler M, et al. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 26: 1713-7. PMID 22382894 DOI: 10.1038/Leu.2012.34 |
0.407 |
|
| 2012 |
Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 742-50. PMID 22291079 DOI: 10.1200/Jco.2011.39.2092 |
0.368 |
|
| 2012 |
O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, ... ... Wetzler M, et al. Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 64-110. PMID 22223870 DOI: 10.6004/Jnccn.2012.0009 |
0.321 |
|
| 2012 |
Damodaran S, Bellavia T, Sait SN, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clinical Colorectal Cancer. 11: 151-4. PMID 22133502 DOI: 10.1016/J.Clcc.2011.09.002 |
0.318 |
|
| 2012 |
Lee HJ, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Is obesity a prognostic factor for acute myeloid leukemia outcome? Annals of Hematology. 91: 359-65. PMID 21935651 DOI: 10.1007/S00277-011-1319-8 |
0.353 |
|
| 2012 |
Wang ES, Zeidan A, Tan W, Wilding GE, Ford LA, Wallace PK, Hahn TE, Battiwalla M, McCarthy PL, Wetzler M. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leukemia & Lymphoma. 53: 2085-8. PMID 21740302 DOI: 10.3109/10428194.2011.603450 |
0.352 |
|
| 2012 |
Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 118: 418-27. PMID 21717444 DOI: 10.1002/Cncr.26292 |
0.466 |
|
| 2012 |
Jarkowski A, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 18: 91-6. PMID 21521799 DOI: 10.1177/1078155211402107 |
0.383 |
|
| 2012 |
Varadarajan R, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Smoking adversely affects survival in acute myeloid leukemia patients. International Journal of Cancer. Journal International Du Cancer. 130: 1451-8. PMID 21520043 DOI: 10.1182/Blood.V114.22.979.979 |
0.325 |
|
| 2012 |
Vigil CE, Griffiths EA, Wang ES, Wetzler M. Improving the Quality of Quantitative Real-Time Polymerase Chain Reaction Laboratory Reporting in Chronic Myeloid Leukemia Labmedicine. 43. DOI: 10.1309/Lmse7M60Tabhdnev |
0.363 |
|
| 2012 |
Wetzler M, Kantarjian H, Nicolini FE, Lipton JH, Akard LP, Baccarani M, Craig A, Brown PD, Cortes JE. Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs). Journal of Clinical Oncology. 30: 6604-6604. DOI: 10.1200/Jco.2012.30.15_Suppl.6604 |
0.424 |
|
| 2012 |
Vigil CE, Griffiths EA, Thompson JE, Tan W, Greene J, Ford LA, Wang ES, Wetzler M. A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia. Journal of Clinical Oncology. 30: 6602-6602. DOI: 10.1200/Jco.2012.30.15_Suppl.6602 |
0.44 |
|
| 2012 |
Akard LP, Kantarjian H, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Craig A, Nanda N, Brown PD, Cortes JE. Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs). Journal of Clinical Oncology. 30: 6596-6596. DOI: 10.1200/Jco.2012.30.15_Suppl.6596 |
0.375 |
|
| 2012 |
Sardesai SD, Tan W, Ford LA, Deeb G, Block AMW, Sait SN, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts). Journal of Clinical Oncology. 30: 6565-6565. DOI: 10.1200/Jco.2012.30.15_Suppl.6565 |
0.328 |
|
| 2012 |
Nicolini FE, Lipton JH, Kantarjian H, Wetzler M, Akard LP, Baccarani M, Craig A, Nanda N, Brown PD, Cortes JE. Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs). Journal of Clinical Oncology. 30: 6513-6513. DOI: 10.1200/Jco.2012.30.15_Suppl.6513 |
0.424 |
|
| 2012 |
Wetzler M, Watson D, Stock W, Owzar K, Koval G, Hoke E, McCarty JM, Blum W, Powell BL, Marcucci G, Bloomfield CD, Linker C, Larson RA. Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) Blood. 120: 816-816. DOI: 10.1182/Blood.V120.21.816.816 |
0.466 |
|
| 2012 |
Lipton JH, Nicolini FE, Wetzler M, Akard L, Baccarani M, Kantarjian HM, Craig A, Cortes JE. Associations Between Baseline Mutation Status and Response to Treatment with Omacetaxine Mepesuccinate in Heavily Pretreated Patients with Chronic Myeloid Leukemia Blood. 120: 4433-4433. DOI: 10.1182/Blood.V120.21.4433.4433 |
0.381 |
|
| 2012 |
Blum W, Sanford B, Klisovic RB, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wetzler M, Hoke E, Bloomfield CD, Geyer S, Marcucci G, Stone RM, et al. Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blood. 120: 44-44. DOI: 10.1182/Blood.V120.21.44.44 |
0.385 |
|
| 2012 |
Khoury HJ, Cortes JE, Wetzler M, Lipton JH, Baccarani M, Douer D, Craig A, Kantarjian HM, Akard L. Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients Blood. 120: 3753-3753. DOI: 10.1182/Blood.V120.21.3753.3753 |
0.45 |
|
| 2012 |
Portwood S, Lal D, Hsu Y, Vargas R, Wetzler M, Wang ES. Activity of the Hypoxia-Activated Prodrug, TH-302, in Human Acute Myeloid Leukemia Models Blood. 120: 3611-3611. DOI: 10.1182/Blood.V120.21.3611.3611 |
0.404 |
|
| 2012 |
Kantarjian HM, Lipton JH, Baccarani M, Nicolini FE, Wetzler M, Akard L, Legros L, Warzocha K, Craig A, Cortes JE. Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. Blood. 120: 2787-2787. DOI: 10.1182/Blood.V120.21.2787.2787 |
0.406 |
|
| 2012 |
Ravandi F, Kadia TM, Borthakur G, Wierda WG, Goldberg SL, Wetzler M, Venugopal P, Seiter K, Chiao J, Kantarjian HM. Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood. 120: 2630-2630. DOI: 10.1182/Blood.V120.21.2630.2630 |
0.416 |
|
| 2012 |
Ganguly S, Kantarjian HM, Wetzler M, Rizzieri D, Schiller G, Hagasia M, Stuart R, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Golberg S, Seiter K, Hari P, et al. Subsequent Hematopoietic Stem Cell Transplantation (HSCT) Associated with Longer Survival in Patients with Relapsed/Refractory (R/R) Acute Myelogenous Leukemia (AML) After Clo+Ara-C or Ara-C Alone: A Landmark Analysis from the Classic I Trial Biology of Blood and Marrow Transplantation. 18. DOI: 10.1016/J.Bbmt.2011.12.026 |
0.358 |
|
| 2011 |
Vigil CE, Tan W, Wilding GE, Garcia-Manero G, Wang ES, Wetzler M, List AF. Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6630. PMID 28020215 DOI: 10.1200/Jco.2011.29.15_Suppl.6630 |
0.428 |
|
| 2011 |
Smonskey M, Starostik P, Deeb G, Demock K, Vargas R, Lal D, Sait SN, Wetzler M, Wang ES. Association of IDH1 mutations in normal karyotype acute myeloid leukemia samples with higher HIF-1α and VEGF-A expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6530. PMID 28020207 DOI: 10.1200/Jco.2011.29.15_Suppl.6530 |
0.327 |
|
| 2011 |
Lee HJ, Wright KM, Kandeel E, Tan W, Wilding GE, Ford LA, Sait SN, Block AM, Barcos MP, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, ... Wetzler M, et al. The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6592. PMID 28020115 DOI: 10.1200/Jco.2011.29.15_Suppl.6592 |
0.348 |
|
| 2011 |
Faderl S, Wetzler M, Rizzieri D, Schiller GJ, Jagasia MH, Stuart RK, Ganguly S, Avigan D, Craig M, Collins R, Maris MB, Kovacsovics T, Goldberg S, Seiter K, Hari P, et al. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6503. PMID 28019994 DOI: 10.1200/Jco.2011.29.15_Suppl.6503 |
0.319 |
|
| 2011 |
Stone RM, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon LE, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Miklos E, Horst H, et al. A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6520. PMID 28019953 DOI: 10.1200/Jco.2011.29.15_Suppl.6520 |
0.372 |
|
| 2011 |
Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 118: 6920-9. PMID 22031865 DOI: 10.1182/Blood-2011-08-368225 |
0.354 |
|
| 2011 |
Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, et al. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica. 96: 1488-95. PMID 21659357 DOI: 10.3324/Haematol.2011.041905 |
0.337 |
|
| 2011 |
Vigil C, Block AW, Wetzler M. The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome. Leukemia & Lymphoma. 52: 943. PMID 21599589 DOI: 10.3109/10428194.2011.580479 |
0.301 |
|
| 2011 |
Almyroudis NG, Lesse AJ, Hahn T, Samonis G, Hazamy PA, Wongkittiroch K, Wang ES, McCarthy PL, Wetzler M, Segal BH. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infection Control and Hospital Epidemiology. 32: 490-6. PMID 21515980 DOI: 10.1086/659408 |
0.347 |
|
| 2011 |
Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer. 117: 1583-94. PMID 21472706 DOI: 10.1002/Cncr.25690 |
0.362 |
|
| 2011 |
Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H. Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer. 117: 4861-8. PMID 21456022 DOI: 10.1002/Cncr.26097 |
0.388 |
|
| 2011 |
Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Reviews. 25: 139-46. PMID 21419537 DOI: 10.1016/J.Blre.2011.02.001 |
0.409 |
|
| 2011 |
Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1373-81. PMID 21343549 DOI: 10.1200/Jco.2010.32.7742 |
0.381 |
|
| 2011 |
O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-25. PMID 21335443 DOI: 10.6004/Jnccn.2011.0125 |
0.408 |
|
| 2011 |
Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Current Pharmaceutical Design. 17: 59-64. PMID 21294709 DOI: 10.2174/138161211795049778 |
0.393 |
|
| 2011 |
Al Ustwani O, Francis J, Wallace PK, Ambrus J, Wetzler M. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. Leukemia Research. 35: e35-6. PMID 21247634 DOI: 10.1016/J.Leukres.2010.12.015 |
0.363 |
|
| 2011 |
Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 487-94. PMID 21220605 DOI: 10.1200/JCO.2010.30.1820 |
0.364 |
|
| 2011 |
Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES. Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leukemia Research. 35: 579-84. PMID 21176961 DOI: 10.1016/J.Leukres.2010.10.020 |
0.355 |
|
| 2011 |
Noor SJ, Tan W, Wilding GE, Ford LA, Barcos M, Sait SN, Block AW, Thompson JE, Wang ES, Wetzler M. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leukemia Research. 35: 608-13. PMID 20727590 DOI: 10.1016/J.Leukres.2010.07.031 |
0.406 |
|
| 2011 |
Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu Y, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, et al. ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category Blood. 118: 417-417. DOI: 10.1182/Blood.V118.21.417.417 |
0.342 |
|
| 2011 |
Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard LP, Craig A, Nanda N, Dial C, Benichou A, Cairati K, Baccarani M, Kennealey GT, Kantarjian HM. Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib, Blood. 118: 3761-3761. DOI: 10.1182/Blood.V118.21.3761.3761 |
0.452 |
|
| 2011 |
Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia T, Borthakur G, Wierda WG, Wetzler M, Venugopal P, Chiao J, Kantarjian HM. Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML, Blood. 118: 3630-3630. DOI: 10.1182/Blood.V118.21.3630.3630 |
0.447 |
|
| 2011 |
Reddy PL, Choppa P, Moradian MM, Potter NT, Quigley MM, Watt CD, Höfling H, Manning B, Mignault A, Mullaney B, Ossa D, Stein A, Wang S, Yang F, Wetzler M. Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed “Virtual” CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study, Blood. 118: 3542-3542. DOI: 10.1182/Blood.V118.21.3542.3542 |
0.365 |
|
| 2011 |
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Kohlschmidt J, Nicolet D, Becker H, Metzeler KH, Schwind S, Whitman SP, Blum W, Powell BL, Kolitz JE, Carter TH, Wetzler M, et al. Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures, Blood. 118: 3454-3454. DOI: 10.1182/Blood.V118.21.3454.3454 |
0.36 |
|
| 2011 |
Liu H, Zhang Y, Hahn T, Thomas J, Wetzler M, Wang ES, Hernandez L, Ross M, Chen GL, McCarthy PL. Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML) Blood. 118: 3096-3096. DOI: 10.1182/Blood.V118.21.3096.3096 |
0.442 |
|
| 2011 |
Koval G, Wetzler M, Watson D, Owzar K, Bloomfield CD, Malnassy G, Sher DA, Larson RA, Stock W. Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001 Blood. 118: 2541-2541. DOI: 10.1182/Blood.V118.21.2541.2541 |
0.381 |
|
| 2011 |
Wetzler M, Kohlschmidt J, Mrózek K, Dombret H, Döhner H, Pilorge S, Krug U, Larson RA, Marcucci G, Hiddemann W, Buchner T, Bloomfield CD. Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)–An International Study Blood. 118: 2521-2521. DOI: 10.1182/Blood.V118.21.2521.2521 |
0.345 |
|
| 2011 |
Griffiths EA, Karpf AR, Odunsi K, James SR, Beck AF, Wetzler M, Ford LA. Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo Blood. 118: 2441-2441. DOI: 10.1182/Blood.V118.21.2441.2441 |
0.341 |
|
| 2011 |
Rondelli D, Goldberg JD, Marchioli R, Isola L, Shore TB, Prchal JT, Bacigalupo A, Rambaldi A, Klisovic RB, Gupta V, Andreasson B, Demakos EP, Price LS, Scarano M, Wetzler M, et al. Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis Blood. 118: 1750-1750. DOI: 10.1182/Blood.V118.21.1750.1750 |
0.39 |
|
| 2011 |
Ghoshal S, Brady MT, Ustwani O, Tracy E, Den Haese J, Wallace PK, Baumann H, Wetzler M. Signal Transducer and Activator of Transcription 3 Promotes Leukemogenesis Blood. 118: 1395-1395. DOI: 10.1182/Blood.V118.21.1395.1395 |
0.326 |
|
| 2011 |
Thudium KE, Haese JD, Karpf A, Fetterly G, Wetzler M. Abstract 5380: Synergistic effects of clofarabine and decitabine in acute myeloid leukemia Cancer Research. 71: 5380-5380. DOI: 10.1158/1538-7445.Am2011-5380 |
0.307 |
|
| 2010 |
Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, Tian L, Mashtare TJ, Murphy M, Prey J, Wetzler M, Fetterly GJ, Wang ES. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Molecular Cancer Therapeutics. 9: 2737-51. PMID 20924124 DOI: 10.1158/1535-7163.Mct-10-0334 |
0.353 |
|
| 2010 |
Wang ES, Sait SN, Gold D, Mashtare T, Starostik P, Ford LA, Wetzler M, Nowak NJ, Deeb G. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer Genetics and Cytogenetics. 202: 101-7. PMID 20875872 DOI: 10.1016/J.Cancergencyto.2010.07.117 |
0.433 |
|
| 2010 |
Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4207-13. PMID 20713865 DOI: 10.1200/Jco.2009.26.8896 |
0.307 |
|
| 2010 |
Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, ... Wetzler M, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 3622-6. PMID 20656931 DOI: 10.1182/Blood-2010-05-283648 |
0.395 |
|
| 2010 |
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 788-92. PMID 20442368 DOI: 10.1182/Blood-2010-01-262543 |
0.422 |
|
| 2010 |
Nowak NJ, Sait SN, Zeidan A, Deeb G, Gaile D, Liu S, Ford L, Wallace PK, Wang ES, Wetzler M. Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics. 199: 15-20. PMID 20417863 DOI: 10.1016/J.Cancergencyto.2010.01.014 |
0.333 |
|
| 2010 |
Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2348-55. PMID 20368543 DOI: 10.1200/Jco.2009.27.3730 |
0.352 |
|
| 2010 |
Ngamphaiboon N, Sweeney R, Wetzler M, Wang ES. Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature. Leukemia Research. 34: e194-6. PMID 20167372 DOI: 10.1016/J.Leukres.2010.01.026 |
0.369 |
|
| 2010 |
Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 116: 1165-76. PMID 20101737 DOI: 10.1002/Cncr.24862 |
0.319 |
|
| 2010 |
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 596-604. PMID 20026798 DOI: 10.1200/Jco.2009.25.1496 |
0.417 |
|
| 2010 |
Lipton JH, Wetzler M, Nicolini F, Baccarani M, Baer MR, Masszi T, Cram D, Benichou A, Nanda N, Cortes JE. Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies. Journal of Clinical Oncology. 28: 6568-6568. DOI: 10.1200/Jco.2010.28.15_Suppl.6568 |
0.388 |
|
| 2010 |
Block AW, Groman AE, Wilding GE, Ford L, Sait SN, Deeb G, Starostik P, Wang ES, Thompson JE, Wetzler M. The role of FLT3 in sole trisomy 8 acute myeloid leukemia. Journal of Clinical Oncology. 28: 6562-6562. DOI: 10.1200/Jco.2010.28.15_Suppl.6562 |
0.452 |
|
| 2010 |
Garcia-Manero G, Luger SM, Venugopal P, Maness LJ, Wetzler M, Altman JK, Claxton D, Strickland SA, Chiao JH, Kantarjian H. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. Journal of Clinical Oncology. 28: 6528-6528. DOI: 10.1200/Jco.2010.28.15_Suppl.6528 |
0.42 |
|
| 2010 |
Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu Y, Blum W, Powell BL, Carter TH, Wetzler M, et al. Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study Blood. 116: 98-98. DOI: 10.1182/Blood.V116.21.98.98 |
0.323 |
|
| 2010 |
Cortes JE, Wetzler M, Lipton J, Nicolini FE, Baccarani M, Baer MR, Khoury HJ, Cram D, Humphriss ED, Benichou A, Craig A, Kantarjian HM. Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure Blood. 116: 2290-2290. DOI: 10.1182/Blood.V116.21.2290.2290 |
0.46 |
|
| 2010 |
Blum W, Donohue K, Marcucci G, DeAngelo DJ, Uy GL, Powell BL, Stock W, Baer M, Kolitz JE, Wetzler M, Hoke E, Moser BK, Larson RA. Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Blood. 116: 2176-2176. DOI: 10.1182/Blood.V116.21.2176.2176 |
0.399 |
|
| 2010 |
Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Altman JK, Claxton DF, Strickland SA, Foran JM, Goldberg SL, Chiao J, Kantarjian HM. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents Blood. 116: 1857-1857. DOI: 10.1182/Blood.V116.21.1857.1857 |
0.401 |
|
| 2010 |
Lee HJ, Muindi J, Wei T, Wilding G, Ford LA, Sait S, Block A, Barcos M, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Johnson CS, Trump D, Wetzler M. Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients. Blood. 116: 1041-1041. DOI: 10.1182/Blood.V116.21.1041.1041 |
0.363 |
|
| 2010 |
Brady MT, Miller A, Sait S, Ford LA, Hans M, Wang ES, Lee KP, Baumann H, Wetzler M. Down-Regulation of Signal Transducer and Activator of Transcription 3 Enhances Acute Myeloid Leukemia-Derived Dendritic Cell Function Blood. 116: 3140-3140. DOI: 10.1182/Blood.V114.22.1972.1972 |
0.33 |
|
| 2010 |
Link PA, Zhang W, Gold D, Wetzler M, Baer MR, Karpf AR. Abstract 190: p53 target gene expression, DNA hypomethylation, and clinical response in MDS patients undergoing decitabine therapy Cancer Research. 70: 190-190. DOI: 10.1158/1538-7445.Am10-190 |
0.365 |
|
| 2009 |
Wetzler M, Hellmann A, Lipton J, Roy L, Jones D, Schenk T, Hochhaus A, Benichou A, Kantarjian H, Cortes J. Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7027. PMID 27961400 DOI: 10.1200/Jco.2009.27.15_Suppl.7027 |
0.374 |
|
| 2009 |
Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H. A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7021. PMID 27961383 DOI: 10.1200/Jco.2009.27.15_Suppl.7021 |
0.362 |
|
| 2009 |
Abutalib SA, Wetzler M, Stock W. Looking Toward the Future: Novel Strategies Based on Molecular Pathogenesis of Acute Lymphoblastic Leukemia Hematology/Oncology Clinics of North America. 23: 1099-1119. PMID 19825455 DOI: 10.1016/J.Hoc.2009.07.004 |
0.313 |
|
| 2009 |
Wetzler M, Stock W. Preface. Acute Lymphoblastic Leukemia - Quo Vadis? Hematology/Oncology Clinics of North America. 23: xi-xviii. PMID 19825446 DOI: 10.1016/J.Hoc.2009.08.001 |
0.354 |
|
| 2009 |
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4754-9. PMID 19720924 DOI: 10.1200/Jco.2008.20.3869 |
0.436 |
|
| 2009 |
Almyroudis NG, Fabian J, Hahn T, Segal BH, Wetzler M, McCarthy PL. Late infectious complications after cord blood stem cell transplantation. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 28: 1405-8. PMID 19672638 DOI: 10.1007/S10096-009-0789-2 |
0.311 |
|
| 2009 |
Radich JP, Zelenetz AD, Chan WC, Croce CM, Czuczman MS, Erba HP, Horning SJ, Houldsworth J, Smith BD, Snyder DS, Sundar HM, Wetzler M, Winter JN. NCCN task force report: molecular markers in leukemias and lymphomas. Journal of the National Comprehensive Cancer Network : Jnccn. 7: S1-34, quiz S35-6. PMID 19635230 DOI: 10.6004/Jnccn.2009.0077 |
0.414 |
|
| 2009 |
Francis J, Smiley S, Battiwalla M, Wetzler M, Barcos M, Bshara W, Paplham P, Brown K, Syta M, Lamonica D, Loud P, McCarthy P. Detection of extra-medullary relapse of acute lymphoblastic leukemia by radiographic imaging following allogeneic hematopoietic SCT. Bone Marrow Transplantation. 44: 827-8. PMID 19633688 DOI: 10.1038/Bmt.2009.183 |
0.342 |
|
| 2009 |
Harb A, Tan W, Wilding GE, Battiwalla M, Sait SN, Wang ES, Wetzler M. Acute myeloid leukemia and diabetes insipidus with monosomy 7. Cancer Genetics and Cytogenetics. 190: 97-100. PMID 19380027 DOI: 10.1016/J.Cancergencyto.2009.01.006 |
0.422 |
|
| 2009 |
Harb AJ, Tan W, Wilding GE, Ford L, Sait SN, Block AW, Barcos M, Wallace PK, Wang ES, Wetzler M. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer. 115: 2472-81. PMID 19322894 DOI: 10.1002/Cncr.24285 |
0.415 |
|
| 2009 |
Zeidan A, Wang ES, Wetzler M. Pegasparaginase: Where do we stand? Expert Opinion On Biological Therapy. 9: 111-119. PMID 19063697 DOI: 10.1517/14712590802586058 |
0.329 |
|
| 2009 |
Drake AS, Brady MT, Wang XH, Sait SJ, Earp JC, Ghoshal Gupta S, Ferrone S, Wang ES, Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunology, Immunotherapy : Cii. 58: 415-27. PMID 18677475 DOI: 10.1007/S00262-008-0567-5 |
0.348 |
|
| 2009 |
Cortes-Franco J, Raghunadharao D, Parikh P, Wetzler M, Lipton JH, Jones D, Hochhaus A, Kantarjian HM, Craig AR, Benichou A, Humphriss E, Nicolini FE. Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study. Blood. 114: 861-861. DOI: 10.1182/Blood.V114.22.861.861 |
0.342 |
|
| 2009 |
Stock W, Sanford B, Lozanski G, Vij R, Byrd JC, Powell BL, Wetzler M, Sher D, Edwards C, Kelly M, Richards S, Sung C, Malnassy G, Hoke E, Bloomfield CD, et al. Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood. 114: 838-838. DOI: 10.1182/Blood.V114.22.838.838 |
0.414 |
|
| 2009 |
Arana Yi CY, Tan W, Wilding G, Ford LA, Sait SN, Block AW, Deeb G, Wallace PK, Starostik P, Thompson JE, Wang ES, Wetzler M. CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease. Blood. 114: 4129-4129. DOI: 10.1182/Blood.V114.22.4129.4129 |
0.303 |
|
| 2009 |
Wetzler M, Wang ES, Shepard R, Thomas DA, Andreeff M, O'Brien S, Kantarjian HM. Phase I Trial of Nanomolecular Liposomal Annamycin in Adult Patients with Refractory Acute Lymphoblastic Leukemia. Blood. 114: 4098-4098. DOI: 10.1182/Blood.V114.22.4098.4098 |
0.42 |
|
| 2009 |
Noor S, Tan W, Wilding G, Ford LA, Barcos M, Sait SN, Block AW, Thompson JE, Wang ES, Wetzler M. Myeloid Blastic Transformation of Myeloproliferative Neoplasms – A Review of 113 Cases. Blood. 114: 3113-3113. DOI: 10.1182/Blood.V114.22.3113.3113 |
0.392 |
|
| 2009 |
McInnis I, Hahn T, Ioane A, Lamson A, Lal D, Ford LA, Sait SN, Starostik P, Deeb G, Wetzler M, Mashtare T, Wang ES. Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML). Blood. 114: 3107-3107. DOI: 10.1182/Blood.V114.22.3107.3107 |
0.399 |
|
| 2009 |
Cortes-Franco J, Coutre S, Bona ED, Lo-Coco F, Wetzler M, Sanz M, Wieland S, Barber JR, Kantarjian HM. A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial). Blood. 114: 2050-2050. DOI: 10.1182/Blood.V114.22.2050.2050 |
0.454 |
|
| 2009 |
Garcia-Manero G, Luger S, Venugopal P, Maness LJ, Wetzler M, Altman J, Claxton DF, Strickland S, Faderl S, Chiao J, Kantarjian HM. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents. Blood. 114: 1758-1758. DOI: 10.1182/Blood.V114.22.1758.1758 |
0.422 |
|
| 2009 |
Kuptsova-Clarkson N, Ambrosone C, Weiss J, Baer MR, Sucheston L, Zirpoli G, Kopecky K, Ford LA, Blanco J, Wetzler M, Moysich K. XPD DNA Nucleotide Excision Repair (NER) Gene Polymorphisms Associated with DNA Repair Deficiency May Predict Better Treatment Outcomes in Secondary Acute Myeloid Leukemia (AML). Blood. 114: 168-168. DOI: 10.1182/Blood.V114.22.168.168 |
0.362 |
|
| 2009 |
Kantarjian HM, Garcia-Manero G, Luger S, Venugopal P, Maness LJ, Wetzler M, Stock W, Coutre S, Borthakur G, Chiao J. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. Blood. 114: 1061-1061. DOI: 10.1182/Blood.V114.22.1061.1061 |
0.431 |
|
| 2008 |
Harb A, Tan W, Wilding GE, Ford LA, Sait SN, Block AW, Barcos M, Wallace PK, Wang ES, Wetzler M. Treating octogenarian and nonagenarian acute myeloid leukemia (AML) patients (pts): Predictive prognostic models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 20576. PMID 27949651 DOI: 10.1200/Jco.2008.26.15_Suppl.20576 |
0.378 |
|
| 2008 |
Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia - A review of 101 cases Annals of Oncology. 19: 1634-1638. PMID 18467310 DOI: 10.1182/Blood.V110.11.4345.4345 |
0.346 |
|
| 2008 |
Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leukemia & Lymphoma. 49: 1274-8. PMID 18452072 DOI: 10.1080/10428190802043887 |
0.403 |
|
| 2008 |
Ghoshal (Gupta) S, Baumann H, Wetzler M. Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia Leukemia Research. 32: 1005-1014. PMID 18192010 DOI: 10.1016/J.Leukres.2007.11.035 |
0.336 |
|
| 2008 |
Zeidan A, Tan W, Wilding G, Ford L, Hahn T, Smiley S, Battiwalla M, McCarthy PL, Wang ES, Wetzler M. Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT). Blood. 112: 952-952. DOI: 10.1182/Blood.V112.11.952.952 |
0.37 |
|
| 2008 |
Cortes J, Seiter K, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey B, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Moore JO. Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study. Blood. 112: 919-919. DOI: 10.1182/Blood.V112.11.919.919 |
0.3 |
|
| 2008 |
Ford J, Behrens A, Vaughan M, Wetzler M, Barcos M, Wang ES. Biclonal (CD34+ CD42b+) Myeloblastic and Megakaryoblastic Transformation of Chronic Myeloproliferative/Myelodysplastic Disorders Blood. 112: 5242-5242. DOI: 10.1182/Blood.V112.11.5242.5242 |
0.413 |
|
| 2008 |
Varadarajan R, Ford L, Sait SN, Block AW, Barcos M, Wallace PK, Ramnath N, Wang ES, Wetzler M. Concomitant Presentation of Acute Myeloid Leukemia (AML) and Lung Cancer Blood. 112: 3994-3994. DOI: 10.1182/Blood.V112.11.3994.3994 |
0.343 |
|
| 2008 |
Cortes J, Paquette R, Talpaz M, Pinilla J, Asatiani E, Wetzler M, Lipton JH, Kasap C, Bui LA, Clary DO, Shah N. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation Blood. 112: 3232-3232. DOI: 10.1182/Blood.V112.11.3232.3232 |
0.35 |
|
| 2008 |
Demock KM, Marinaro J, McInnis I, Ford LA, Wetzler M, Tian L, Deeb G, Wang ES. Hypoxia-Inducible Factor-1 Alpha (HIF-1α) and HIF-2α Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML) Blood. 112: 2553-2553. DOI: 10.1182/Blood.V112.11.2553.2553 |
0.334 |
|
| 2008 |
Demock KM, Marinaro J, Sobczyk A, Ford LA, Wetzler M, Deeb G, Tian L, Wang ES. Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML) Blood. 112: 2552-2552. DOI: 10.1182/Blood.V112.11.2552.2552 |
0.358 |
|
| 2007 |
Zeidan A, Kakati S, Anderson B, Barcos M, Wetzler M. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case Cancer Genetics and Cytogenetics. 176: 169-171. PMID 17656263 DOI: 10.1016/J.Cancergencyto.2006.12.011 |
0.408 |
|
| 2007 |
Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS, Rowe JM, Wetzler M, Weisdorf DJ. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 110: 409-17. PMID 17374741 DOI: 10.1182/Blood-2006-10-043299 |
0.39 |
|
| 2007 |
Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 109: 4164-7. PMID 17264295 DOI: 10.1182/Blood-2006-09-045351 |
0.387 |
|
| 2007 |
Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz JE, Thakuri M, Carter T, Stuart RK, Larson RA. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old Journal of Clinical Oncology. 25: 7012-7012. DOI: 10.1200/Jco.2007.25.18_Suppl.7012 |
0.39 |
|
| 2007 |
Zeidan A, Gaile D, Conroy JM, McQuaid DE, Wang ES, Deeb G, Wallace PK, Sait SNJ, Nowak NJ, Wetzler M. Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia (pB-ALL) Detected by Comparative Genomic Hybridization. Blood. 110: 4270-4270. DOI: 10.1182/Blood.V110.11.4270.4270 |
0.326 |
|
| 2007 |
Lancet JE, Gotlib J, Wetzler M, Luger S, Cripe LD, Tallman MS, Gojo I, Mulford D, Baer MR, List AF, Multani PS, Sikic BI. Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML). Blood. 110: 299-299. DOI: 10.1182/Blood.V110.11.299.299 |
0.449 |
|
| 2007 |
Wetzler M, Stock W, Donohue KA, Owzar K, Sher DA, Hoke EE, McCarty JM, Blum WG, Powell BL, Bloomfield CD, Linker CA, Larson RA. Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001. Blood. 110: 2869-2869. DOI: 10.1182/Blood.V110.11.2869.2869 |
0.44 |
|
| 2007 |
Wang ES, Sobczyk A, Marinaro JM, Wetzler M, Tian L, Deeb G. VEGF-A, VEGF-C, and CD31 Expression by Leukemia Cells Are Prognostic Factors for Overall Survival in Acute Myeloid Leukemia (AML). Blood. 110: 2392-2392. DOI: 10.1182/Blood.V110.11.2392.2392 |
0.349 |
|
| 2006 |
Wetzler M, Brady MT, Tracy E, Li ZR, Donohue KA, O'Loughlin KL, Cheng Y, Mortazavi A, McDonald AA, Kunapuli P, Wallace PK, Baer MR, Cowell JK, Baumann H. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6817-25. PMID 17121903 DOI: 10.1158/1078-0432.Ccr-06-1354 |
0.321 |
|
| 2006 |
Minderman H, O'Loughlin KL, Smith PF, Pendyala L, Greco WR, Sweeney KG, Ford LA, Wetzler M, Baer MR. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 57: 73-83. PMID 16010591 DOI: 10.1007/S00280-005-0017-4 |
0.42 |
|
| 2006 |
Claus JA, Brady MT, Lee J, Donohue KA, Sait SN, Ferrone S, Wetzler M. T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression. Cancer Immunology, Immunotherapy : Cii. 55: 160-5. PMID 16010586 DOI: 10.1007/S00262-005-0012-Y |
0.303 |
|
| 2006 |
Wetzler M, Stock W, Owzar K, Sher DA, Hoke EE, Linker CA, Bloomfield CD, Larson RA. Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL)—Preliminary results of CALGB 10001 Journal of Clinical Oncology. 24: 6549-6549. DOI: 10.1200/Jco.2006.24.18_Suppl.6549 |
0.407 |
|
| 2006 |
Baer MR, Ford LA, Bundy BN, Tighe SM, O’Loughlin KL, Slack JL, Wetzler M, Wallace PK. Randomized Trial of GM-CSF and G-CSF Following High-Dose Cytarabine and Mitoxantrone Chemotherapy for Relapsed and Refractory Acute Leukemia. Blood. 108: 4574-4574. DOI: 10.1182/Blood.V108.11.4574.4574 |
0.44 |
|
| 2006 |
Drake AS, Michael BT, Wang XH, Sait SJ, Earp JC, Jusko WJ, Ferrone S, Wang ES, Wetzler M. The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells. Blood. 108: 4550-4550. DOI: 10.1182/Blood.V108.11.4550.4550 |
0.394 |
|
| 2006 |
Wojtaszczyk JA, Hahn T, Battiwalla M, Baer MR, Wang E, Barcos M, Bambach B, Padmanabhan S, Wetzler M, McCarthy PL. Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT). Blood. 108: 3033-3033. DOI: 10.1182/Blood.V108.11.3033.3033 |
0.401 |
|
| 2005 |
Pawarode A, Baer MR, Padmanabhan S, Wallace PK, Barcos M, Sait SNJ, Block AW, Wetzler M, Battiwalla M. Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: Case report and review of the literature Leukemia and Lymphoma. 46: 1813-1818. PMID 16263586 DOI: 10.1080/10428190500244258 |
0.311 |
|
| 2005 |
Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuczman M, McCarthy PL, Walsh TJ, Segal BH. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia. 159: 181-8. PMID 15770441 DOI: 10.1007/S11046-004-5495-0 |
0.35 |
|
| 2005 |
Wetzler M, Brady MT, Donohue KA, Lee S, Tighe SM, Ford LA, Wang ES, Baer MR, Baumann H. Targeting signal transducer and activator of transcription 3 protein with arsenic trioxide: A phase I clinical trial Journal of Clinical Oncology. 23: 6538-6538. DOI: 10.1200/Jco.2005.23.16_Suppl.6538 |
0.389 |
|
| 2005 |
Wetzler M, Brady MT, Siat SN, Kakati S, Block AW, Wang X, Hunger SP, Carroll AJ, Ferrone S. Differential Antigenic Profile of High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Expressed by 11q23-Positive Acute Leukemia: An Immunotherapeutic Target. Blood. 106: 3261-3261. DOI: 10.1182/Blood.V106.11.3261.3261 |
0.315 |
|
| 2005 |
Stock W, Johnson J, Yu D, Bennett D, Sher D, Stone RM, Kolitz JE, Powell BL, Wetzler M, Vardiman JW, Bloomfield CD, Larson RA. Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. Blood. 106: 1833-1833. DOI: 10.1182/Blood.V106.11.1833.1833 |
0.397 |
|
| 2005 |
Stock W, Yu D, Sanford B, Lozanski G, Cataland S, Vij R, Byrd J, Powell B, Wetzler M, Albitar M, Sher D, Edwards C, Hoke E, Bloomfield CD, Larson RA. Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). Blood. 106: 145-145. DOI: 10.1182/Blood.V106.11.145.145 |
0.373 |
|
| 2005 |
Wetzler M, Yu D, Odenike O, Feldman EJ, Hurd DD, Hoke E, Hars V, Larson RA. Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107. Blood. 106: 1097-1097. DOI: 10.1182/Blood.V106.11.1097.1097 |
0.395 |
|
| 2004 |
Hahn T, Alam AR, Lawrence D, Ford L, Baer MR, Bambach B, Bernstein ZP, Czuczman MS, Silva J, Slack JL, Wetzler M, Becker J, McCarthy PL. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion Transplantation. 78: 1515-1522. PMID 15599317 DOI: 10.1097/01.Tp.0000141363.81600.0D |
0.329 |
|
| 2004 |
Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, Wetzler M, Ross DD, Baer MR. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: Frequent expression and possible correlation with shorter disease-free survival British Journal of Haematology. 127: 392-398. PMID 15521915 DOI: 10.1111/J.1365-2141.2004.05211.X |
0.314 |
|
| 2004 |
Kansal R, Deeb G, Barcos M, Wetzler M, Brecher ML, Block AW, Stewart CC. Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction: a report of 15 patients. American Journal of Clinical Pathology. 121: 512-25. PMID 15080303 DOI: 10.1309/Wtxc-Q5Nr-Acvx-Tyby |
0.304 |
|
| 2004 |
Wetzler M, Dodge RK, Mrózek K, Stewart CC, Carroll AJ, Tantravahi R, Vardiman JW, Larson RA, Bloomfield CD. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. British Journal of Haematology. 124: 275-88. PMID 14717774 DOI: 10.1046/J.1365-2141.2003.04736.X |
0.348 |
|
| 2004 |
Iyer RV, Sait SN, Matsui S, Block AW, Barcos M, Slack JL, Wetzler M, Baer MR. Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. Cancer Genetics and Cytogenetics. 148: 29-34. PMID 14697638 DOI: 10.1016/S0165-4608(03)00214-0 |
0.433 |
|
| 2004 |
Kansal R, Deeb G, Barcos M, Wetzler M, Brecher ML, Block AW, Stewart CC. Precursor B Lymphoblastic Leukemia With Surface Light Chain Immunoglobulin Restriction American Journal of Clinical Pathology. 121: 512-525. DOI: 10.1309/Wtxcq5Nracvxtyby |
0.312 |
|
| 2004 |
Ramanarayanan J, Baer AN, Battiwalla M, Ford LA, Wetzler M, Baer MR. Autoimmune Disease (AD) in Patients with Myelodysplastic Syndrome (MDS): A Retrospective Single Institution Study. Blood. 104: 4736-4736. DOI: 10.1182/Blood.V104.11.4736.4736 |
0.366 |
|
| 2003 |
Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia. 17: 707-15. PMID 12682628 DOI: 10.1038/Sj.Leu.2402865 |
0.322 |
|
| 2002 |
Bernstein SH, Jusko WJ, Krzyzanski W, Nichol J, Wetzler M. Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. Journal of Clinical Pharmacology. 42: 501-11. PMID 12017344 DOI: 10.1177/00912700222011553 |
0.348 |
|
| 2002 |
Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, Wetzler M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 99: 252-7. PMID 11756179 DOI: 10.1182/Blood.V99.1.252 |
0.397 |
|
| 2001 |
Kolte B, Baer AN, Sait SN, O'Loughlin KL, Stewart CC, Barcos M, Wetzler M, Baer MR. Acute myeloid leukemia in the setting of low dose weekly methotrexate therapy for rheumatoid arthritis. Leukemia & Lymphoma. 42: 371-8. PMID 11699401 DOI: 10.3109/10428190109064593 |
0.401 |
|
| 2001 |
Barone S, Baer MR, Sait SNJ, Lawrence D, Block AW, Wetzler M. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. American Journal of Hematology. 67: 119-124. PMID 11343384 DOI: 10.1002/Ajh.1089 |
0.453 |
|
| 2001 |
Xia Z, Sait SN, Baer MR, Barcos M, Donohue KA, Lawrence D, Ford LA, Block AM, Baumann H, Wetzler M. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leukemia Research. 25: 473-82. PMID 11337019 DOI: 10.1016/S0145-2126(00)00158-2 |
0.384 |
|
| 2001 |
Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia. 15: 128-33. PMID 11243380 DOI: 10.1038/Sj.Leu.2401982 |
0.32 |
|
| 2000 |
Wetzler M. Cytogenetics in adult acute lymphocytic leukemia. Hematology-Oncology Clinics of North America. 14: 1237-1249. PMID 11147221 DOI: 10.1016/S0889-8588(05)70184-2 |
0.431 |
|
| 2000 |
Wetzler M, Lincoff N. Unusual Manifestations of Acute Leukemia Journal of Clinical Oncology. 18: 3439-3440. PMID 11013286 DOI: 10.1200/Jco.2000.18.19.3439 |
0.352 |
|
| 1999 |
Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplantation. 24: 1311-4. PMID 10627640 DOI: 10.1038/Sj.Bmt.1702069 |
0.399 |
|
| 1999 |
Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH, Czuczman MS, Slack JL, Spangenthal E, Wetzler M, Barcos MP, Proulx GM, Anderson B, McCarthy PL. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: Association with the female sex and cardiac risk factors Biology of Blood and Marrow Transplantation. 5: 322-327. PMID 10534063 DOI: 10.1016/S1083-8791(99)70008-X |
0.314 |
|
| 1999 |
Wetzler M, Dodge RK, Mrózek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Beau MML, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 93: 3983-3993. DOI: 10.1182/Blood.V93.11.3983.411K14_3983_3993 |
0.407 |
|
| 1998 |
Shah M, Jenis EH, Mookerjee BK, Schriber JR, Baer MR, Herzig GP, Wetzler M. Interferon-α-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy Cancer. 83: 1938-1946. PMID 9806652 DOI: 10.1002/(Sici)1097-0142(19981101)83:9<1938::Aid-Cncr9>3.0.Co;2-M |
0.314 |
|
| 1998 |
Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart C, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. Leukemia & Lymphoma. 30: 415-31. PMID 9711904 DOI: 10.3109/10428199809057554 |
0.372 |
|
| 1997 |
Wetzler M, Kurzrock R, Estrov Z, Barone S, Estey E, Talpaz M. Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. Leukemia Research. 21: 519-27. PMID 9279363 DOI: 10.1016/S0145-2126(97)00005-2 |
0.305 |
|
| 1997 |
Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrózek K, Block AW, Herzig GP, Bloomfield CD. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 2262-8. PMID 9196139 DOI: 10.1200/Jco.1997.15.6.2262 |
0.375 |
|
| 1997 |
Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M. Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Leukemia & Lymphoma. 25: 121-33. PMID 9130620 DOI: 10.3109/10428199709042502 |
0.344 |
|
| 1996 |
Wetzler M, Kurzrock R, Goodacre AM, McLaughlin P, Ku S, Talpaz M. Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Cancer. 76: 609-17. PMID 8625154 DOI: 10.1002/1097-0142(19950815)76:4<609::Aid-Cncr2820760411>3.0.Co;2-Y |
0.37 |
|
| 1995 |
Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-alpha therapy for chronic myelogenous leukemia. The American Journal of Medicine. 99: 402-11. PMID 7573097 DOI: 10.1016/S0002-9343(99)80189-2 |
0.303 |
|
| 1994 |
Wetzler M, Talpaz M, Estrov Z, Kurzrock R. CML: mechanisms of disease initiation and progression. Leukemia & Lymphoma. 47-50. PMID 8251916 DOI: 10.3109/10428199309047863 |
0.34 |
|
| 1994 |
Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, Ben-Neriah Y. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proceedings of the National Academy of Sciences of the United States of America. 91: 10722-6. PMID 7938018 DOI: 10.1073/Pnas.91.22.10722 |
0.312 |
|
| 1993 |
Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. The Journal of Clinical Investigation. 92: 1925-39. PMID 8408645 DOI: 10.1172/Jci116786 |
0.337 |
|
| 1993 |
Estrov Z, Talpaz M, Wetzler M, Kurzrock R. The modulatory hematopoietic activities of leukemia inhibitory factor. Leukemia & Lymphoma. 8: 1-7. PMID 1493463 DOI: 10.3109/10428199209049811 |
0.319 |
|
| 1991 |
Wetzler M, Kurzrock R, Lowe D, Kantarjian H, Gutterman J, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression Blood. 78: 2400-2406. DOI: 10.1182/Blood.V78.9.2400.2400 |
0.315 |
|
| Show low-probability matches. |